Orthocell (ASX:OCC) share price surges 13% on study success

Shares in the medical company are surging today.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success.

At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%.

Orthocell is developing new medical devices and cellular therapies to help people recover from injury.

Why is the share price surging?

It appears investors are responding to positive results from a clinical trial into the use of one of Orthocell's lead products, OrthoATI.

In today's release, Orthocell said its data confirmed this product could safely reduce pain in patients suffering from rotator cuff tears. OrthoATI is more effective than steroid injections for treating this injury, according to the company.

Orthocell now plans to speed up its commercialisation plans for OrthoATI in the United States, including conducting a study in front of the Food and Drug Administration.

Orthocell told the market today it believed it could use its OrthoATI treatment to help 480,000 patients per year in the US alone. The company sees this as a US$4 to $5 billion market opportunity (AU $5.6 to $7 billion).

Management commentary

Orthocell managing director Paul Anderson welcomed the news, saying it was an important milestone. He added:

We are absolutely delighted with the study results for this challenging and debilitating condition which clearly demonstrates that OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.

Orthocell share price snapshot

The Orthocell share price has lifted more than 38% in the past 12 months and is up 27.78% this year to date.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% in the past year.

Shares in the company reached a 52-week high of 66 cents, while the low was 40.5 cents.

Should you invest $1,000 in Orthocell Limited right now?

Before you buy Orthocell Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Orthocell Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is this ASX 200 healthcare share leaping 14% today?

Clarity Pharmaceuticals is the biggest gainer of the ASX 200 on Tuesday.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

Guess which ASX All Ords stock just leapt 9% on big US news

Investors are piling into this ASX All Ords stock on Tuesday. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Up 290% in 12 months: Why this ASX healthcare stock is surging again today

This stock is continuing its ascent on Tuesday. But why?

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Healthcare Shares

CSL is approaching a 5-year low. Is this a buying opportunity?

Let's see if analysts think investors should be buying the dip with this quality stock.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Pro Medicus shares are down 20%. Is this a buying opportunity?

One of the ASX’s best companies is now materially cheaper.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Orthocell shares up 10% today; anticipates FDA approval in the coming weeks

Some big news could be just days away for this growing regenerative medicine company.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

A quality ASX 200 share with 'limited to no impact' from Donald Trump's tariffs

A leading expert believes this ASX 200 company is now at an “attractive entry point”.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »